Long-term therapy with bevacizumab in a patient with Glanzmann's thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions

Am J Gastroenterol. 2015 Feb;110(2):352-3. doi: 10.1038/ajg.2014.391.

Authors

Raphael Marlu¹, J Barthelon², A Durand², N Mathieu², C Barro¹, V Granger², A Tatu², G Pernod³, B Polack¹, B Bonaz²

Affiliations

¹ Hemostasis Unit, University Hospital, Grenoble, France.
² Gastroenterology Unit, University Hospital, Grenoble, France.
³ Vascular Medical Unit, University Hospital, Grenoble, France.

PMID: 25646919
DOI: 10.1038/ajg.2014.391

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Angiodysplasia / complications*
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Bevacizumab
Female
Gastrointestinal Hemorrhage / etiology
Gastrointestinal Hemorrhage / prevention & control*
Humans
Maintenance Chemotherapy
Middle Aged
Thrombasthenia / complications*
Treatment Outcome

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Bevacizumab